title: Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen.
authors.forename: P
authors.initials: P
authors.lastname: Brazzola
authors.forename: M
authors.initials: M
authors.lastname: Duval
authors.forename: J C
authors.initials: JC
authors.lastname: Fournet
authors.forename: F
authors.initials: F
authors.lastname: Gauvin
authors.forename: J H
authors.initials: JH
authors.lastname: Dalle
authors.forename: J
authors.initials: J
authors.lastname: Champagne
authors.forename: M A
authors.initials: MA
authors.lastname: Champagne
mesh_terms: D000293:Adolescent; D002196:Capillaries / Q000473:pathology*; D002543:Cerebral Hemorrhage / Q000628:therapy; D016572:Cyclosporine / Q000494:pharmacology; D019871:Dyskeratosis Congenita / Q000401:mortality* / Q000628:therapy*; D017707:Erythrocyte Transfusion; D004947:Esophagus / Q000473:pathology; D006086:Graft vs Host Disease / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D009092:Mucous Membrane / Q000473:pathology; D009336:Necrosis; D017713:Platelet Transfusion; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods*; D014652:Vascular Diseases / Q000209:etiology* / Q000401:mortality*
chemical_list: D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D016572:Cyclosporine